{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:10:44Z","timestamp":1792084244894,"version":"4.4.0"},"reference-count":87,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>There is increasing evidence for the presence of pathological forms of tau in tissues of both Huntington\u2019s disease (HD) patients and animal models of this condition. While cumulative studies of the past decade have led to the proposition that this disorder could also be considered a tauopathy, the implications of tau in cellular toxicity and consequent behavioral impairments are largely unknown. In fact, recent animal work has challenged the contributory role of tau in HD pathogenesis\/pathophysiology. This review presents the supporting and opposing arguments for the involvement of tau in HD, highlighting the discrepancies that have emerged. Reflecting on what is known in other tauopathies, the putative mechanisms through which tau could initiate and\/or contribute to pathology are discussed, shedding light on the future research directions that could be considered to confirm, or rule out, the clinical relevance of tau in HD.<\/jats:p>","DOI":"10.3233\/jhd-220557","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T10:51:01Z","timestamp":1676371861000},"page":"15-29","source":"Crossref","is-referenced-by-count":22,"title":["Untangling the Role of Tau in Huntington\u2019s Disease Pathology"],"prefix":"10.1177","volume":"12","author":[{"given":"Shireen","family":"Salem","sequence":"first","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences, Qu\u00e9bec, QC, Canada"},{"name":"D\u00e9partement de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences, Qu\u00e9bec, QC, Canada"},{"name":"D\u00e9partement de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"},{"name":"D\u00e9partement de Psychiatrie & Neurosciences, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-220557_ref1","first-page":"971","article-title":"The Huntington\u2019s Disease Collaborative Research Grou","volume":"72","author":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","year":"1993","journal-title":"Cell"},{"key":"10.3233\/JHD-220557_ref2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JHD-220557_ref3","article-title":"Tau: A common denominator and therapeutic target for neurodegenerative disorders","volume":"12","author":"Maxan","year":"2380","journal-title":"J Exp Neurosci"},{"key":"10.3233\/JHD-220557_ref4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/369488a0","article-title":"Altered microtubule organization in small-calibre axons of mice lacking tau protein","volume":"369","author":"Harada","year":"1994","journal-title":"Nature"},{"key":"10.3233\/JHD-220557_ref5","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1074\/jbc.M110.199976","article-title":"Nuclear tau, a key player in neuronal DNA protection","volume":"286","author":"Sultan","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-220557_ref6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JHD-220557_ref7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40478-017-0491-z","article-title":"EuroTau: Towing scientists to tau without tautology","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JHD-220557_ref8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.3233\/JHD-220557_ref9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1074\/jbc.270.2.823","article-title":"Proline-directed and non-proline-directed phosphorylation of PHF-tau","volume":"270","author":"Morishima-Kawashima","year":"1995","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-220557_ref10","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JHD-220557_ref11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s007020050095","article-title":"Alzheimer-type lesions in Huntington\u2019s disease","volume":"105","author":"Jellinger","year":"1998","journal-title":"J Neural Transm"},{"key":"10.3233\/JHD-220557_ref12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JHD-220557_ref13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.35.2.273","article-title":"Dementia of the Alzheimer\u2019s type and Huntington\u2019s disease","volume":"35","author":"Reyes","year":"1985","journal-title":"Neurology"},{"key":"10.3233\/JHD-220557_ref14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1532-5415.1988.tb01807.x","article-title":"The coexistence and differentiation of late onset Huntington\u2019s disease and Alzheimer\u2019s disease. A case report and review of the literature","volume":"36","author":"Moss","year":"1988","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JHD-220557_ref15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ana.410030616","article-title":"Huntington disease associated with Alzheimer disease","volume":"3","author":"McIntosh","year":"1978","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-220557_ref16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/jnnp.48.6.530","article-title":"Late onset of Huntington\u2019s disease","volume":"48","author":"Myers","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-220557_ref17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JHD-140111","article-title":"The co-occurrence of Alzheimer\u2019s disease and Huntington\u2019s disease: A neuropathological study of 15 elderly Huntington\u2019s disease subjects","volume":"3","author":"Davis","year":"2014","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-220557_ref18","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JHD-220557_ref19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm.3617","article-title":"Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods","volume":"20","author":"Fern\u00e1ndez-Nogales","year":"2014","journal-title":"Nat Med"},{"key":"10.3233\/JHD-220557_ref21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/hmg\/ddu456","article-title":"Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington\u2019s disease","volume":"24","author":"Gratuze","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/hmg\/ddu421","article-title":"Mutant huntingtin alters tau phosphorylation and subcellular distribution","volume":"24","author":"Blum","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s12035-021-02698-y","article-title":"Quantitative phosphoproteomics reveals extensive protein phosphorylation dysregulation in the cerebral cortex of Huntington\u2019s disease mice prior to onset of symptoms","volume":"59","author":"Mees","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JHD-220557_ref24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ymthe.2022.01.020","article-title":"Passive immunization against phosphorylated tau improves features of Huntington\u2019s disease pathology","volume":"30","author":"Alpaugh","year":"2022","journal-title":"Mol Ther"},{"key":"10.3233\/JHD-220557_ref25","doi-asserted-by":"crossref","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","article-title":"GSK-3\u03b2-induced tau pathology drives hippocampal neuronal cell death in Huntington\u2019s disease: Involvement of astrocyte-neuron interactions","volume":"7","author":"L\u2019Episcopo","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.3233\/JHD-220557_ref26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","article-title":"Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation","volume":"12","author":"Hughes","year":"1993","journal-title":"EMBO J"},{"key":"10.3233\/JHD-220557_ref27","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1093\/hmg\/ddv224","article-title":"Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington\u2019s disease","volume":"24","author":"Fern\u00e1ndez-Nogales","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref28","first-page":"4792","article-title":"Deconstructing GSK- The fine regulation of its activity","volume":"3","author":"Medina","year":"2011","journal-title":"Int J Alzheimers Dis"},{"key":"10.3233\/JHD-220557_ref29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cdd.2009.127","article-title":"PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K\/Akt pro-survival pathway in Huntington\u2019s disease striatum","volume":"17","author":"Saavedra","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.3233\/JHD-220557_ref30","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington\u2019s disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JHD-220557_ref31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.nbd.2021.105336","article-title":"Inhibition of GSK-3 ameliorates the pathogenesis of Huntington\u2019s disease","volume":"154","author":"Rippin","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JHD-220557_ref32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington\u2019s disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nbd.2009.08.012","article-title":"Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington\u2019s disease: Role in excitotoxicity","volume":"36","author":"Xifr\u00f3","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JHD-220557_ref34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington\u2019s disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref35","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"PNAS"},{"key":"10.3233\/JHD-220557_ref36","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jmb.2019.01.034","article-title":"Deregulated splicing is a major mechanism of RNA-induced toxicity in Huntington\u2019s disease","volume":"431","author":"Schilling","year":"2019","journal-title":"J Mol Biol"},{"key":"10.3233\/JHD-220557_ref37","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1074\/jbc.M413846200","article-title":"Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1","volume":"280","author":"Wang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-220557_ref39","doi-asserted-by":"crossref","first-page":"30497","DOI":"10.1074\/jbc.M112.355412","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine\/arginine-rich protein 55 (SRp55)-promoted tau exon 10 inclusion","volume":"287","author":"Yin","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-220557_ref40","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fncel.2019.00574","article-title":"Altered levels and isoforms of tau and nuclear membrane invaginations in Huntington\u2019s disease","volume":"13","author":"Fern\u00e1ndez-Nogales","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JHD-220557_ref41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","article-title":"Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport","volume":"40","author":"Szebenyi","year":"2003","journal-title":"Neuron"},{"key":"10.3233\/JHD-220557_ref42","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1073\/pnas.2034961100","article-title":"Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington\u2019s disease","volume":"100","author":"Trushina","year":"2003","journal-title":"PNAS"},{"key":"10.3233\/JHD-220557_ref43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/jcs.115.5.941","article-title":"Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: Relevance to Huntington\u2019s disease","volume":"115","author":"Hoffner","year":"2002","journal-title":"J Cell Sci"},{"key":"10.3233\/JHD-220557_ref44","first-page":"1","article-title":"Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells","volume":"275","author":"Wellington","year":"1983","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-220557_ref45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1750-1326-6-59","article-title":"Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease","volume":"6","author":"Carroll","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JHD-220557_ref46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40478-019-0764-9","article-title":"A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington\u2019s disease patients","volume":"7","author":"Liu","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JHD-220557_ref47","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/nm.4199","article-title":"Caspase-2 cleavage of tau reversibly impairs memory","volume":"22","author":"Zhao","year":"2016","journal-title":"Nat Med"},{"key":"10.3233\/JHD-220557_ref48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/mds.22204","article-title":"Association of corticobasal degeneration and Huntington\u2019s disease: Can tau aggregates protect Huntingtin toxicity","volume":"24","author":"Caparros-Lefebvre","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-220557_ref49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JHD-220557_ref50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.dadm.2019.07.007","article-title":"Tau pathology in cognitively normal older adults","volume":"11","author":"Ziontz","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JHD-220557_ref51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JHD-220557_ref52","first-page":"A27 LP","article-title":"D21 Analysis of blood and CSF biomarkers in mouse models of Huntington\u2019s disease","volume":"93","author":"Bondulich","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-220557_ref53","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1093\/hmg\/ddac001","article-title":"Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington\u2019s disease","volume":"31","author":"Mees","year":"2022","journal-title":"Hum Mol Genet.-"},{"key":"10.3233\/JHD-220557_ref54","doi-asserted-by":"crossref","first-page":"190574","DOI":"10.1098\/rsos.190574","article-title":"Contrasting characteristic behaviours among common laboratory mouse strains","volume":"6","author":"Sultana","year":"2019","journal-title":"R Soc Open Sci"},{"key":"10.3233\/JHD-220557_ref55","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1093\/hmg\/ddu119","article-title":"Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington\u2019s disease affected brain","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-220557_ref56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-6606-2-33","article-title":"Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington\u2019s disease","volume":"2","author":"Pineda","year":"2009","journal-title":"Mol Brain"},{"key":"10.3233\/JHD-220557_ref57","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1523\/JNEUROSCI.3706-05.2006","article-title":"Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421","volume":"26","author":"Pardo","year":"2006","journal-title":"J Neurosci"},{"key":"10.3233\/JHD-220557_ref58","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington\u2019s disease and involves Huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev Cell"},{"key":"10.3233\/JHD-220557_ref59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1212\/WNL.45.4.788","article-title":"Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"45","author":"Vigo-Pelfrey","year":"1995","journal-title":"Neurology"},{"key":"10.3233\/JHD-220557_ref60","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archneur.55.7.937","article-title":"High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype","volume":"55","author":"Galasko","year":"1998","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-220557_ref61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-220557_ref62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-170129","article-title":"PET tau and amyloid-\u03b2 burden in mild Alzheimer\u2019s disease: Divergent relationship with age, cognition, and cerebrospinal fluid biomarkers","volume":"60","author":"Koychev","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JHD-220557_ref63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","article-title":"Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile","volume":"3","author":"Winston","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JHD-220557_ref64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40120-017-0075-7","article-title":"Detection of plasma biomarkers using immunomagnetic reduction: A promising method for the early diagnosis of Alzheimer\u2019s disease","volume":"6","author":"Yang","year":"2017","journal-title":"Neurol Ther"},{"key":"10.3233\/JHD-220557_ref65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2011-101641","article-title":"Human platelets tau: A potential peripheral marker for Alzheimer\u2019s disease","volume":"25","author":"Neumann","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JHD-220557_ref66","first-page":"313","article-title":"Tau-protein expression in human blood lymphocytes: A promising marker and suitable sample for life-time diagnosis of Alzheimer\u2019s disease","volume":"21","author":"Kvetnoy","year":"2000","journal-title":"Neuro Endocrinol Lett"},{"key":"10.3233\/JHD-220557_ref67","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3233\/JAD-2011-110731","article-title":"Salivary tau species are potential biomarkers of Alzheimer\u2019s disease","volume":"27","author":"Shi","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JHD-220557_ref68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fneur.2017.00554","article-title":"Tau protein in oral mucosa and cognitive state: A cross-sectional study","volume":"8","author":"Arredondo","year":"2017","journal-title":"Front Neurol"},{"key":"10.3233\/JHD-220557_ref69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-220557_ref70","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.3233\/JHD-220557_ref72","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/alz.12452","article-title":"Current directions in tau research: Highlights from Tau 2020","volume":"18","author":"Sexton","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JHD-220557_ref73","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the Lewy body diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.3233\/JHD-220557_ref74","doi-asserted-by":"crossref","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.3233\/JHD-220557_ref75","first-page":"A44 LP","article-title":"D26 Pathological tau signal in Huntington\u2019s disease \u2013an in vivo-AV-pet imaging report","volume":"87","author":"Reetz","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-220557_ref76","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/JHD-220557_ref77","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington\u2019s disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JHD-220557_ref78","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.3233\/JHD-220557_ref79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JHD-229002","article-title":"Huntington\u2019s disease clinical trials corner: April","volume":"11","author":"Estevez-Fraga","year":"2022","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-220557_ref80","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JHD-220557_ref81","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.3389\/fneur.2020.580732","article-title":"Targeting tau to treat clinical features of Huntington\u2019s disease","volume":"11","author":"Masnata","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JHD-220557_ref82","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2009","journal-title":"PNAS"},{"key":"10.3233\/JHD-220557_ref83","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JHD-220557_ref84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JHD-220557_ref85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","article-title":"Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington\u2019s disease mutation","volume":"61","author":"Wood","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.3233\/JHD-220557_ref86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0019-5545.105522","article-title":"Off label use of lithium in the treatment of Huntington\u2019s disease: A case series","volume":"55","author":"Danivas","year":"2013","journal-title":"Indian J Psychiatry"},{"key":"10.3233\/JHD-220557_ref88","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"10.3233\/JHD-220557_ref89","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JHD-220557_ref90","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain.-"},{"key":"10.3233\/JHD-220557_ref91","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-220557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:13Z","timestamp":1777452973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-220557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":87,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-220557","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}